OTC:YBGJ
Yubo International Biotech Ltd
A biotech developer targeting niche therapeutic markets with a focus on innovative medical technologies and clinical-stage product pipelines.
Key Metrics
Investment Thesis
Bull Case
An investor might consider YBGJ if they believe in the high-potential upside of early-stage biotech firms where a single successful asset can multiply value exponentially. The company's asset-heavy profile, indicated by significant intangible assets and long-term operating lease assets, suggests a dedicated infrastructure for R&D that could yield breakthrough products upon approval. Additionally, any upcoming strategic partnerships or licensing deals could provide the necessary cash infusion to stabilize operations and validate the management team's execution capabilities.
Bear Case
The stock is highly speculative given the company's negative shareholders' equity of $3.3M and a complete absence of revenue in 2024, signaling potential business model failure or commercialization delays. Investors should avoid this ticker due to the dangerous liquidity profile where current liabilities ($4.7M) dwarf current assets ($682k), raising immediate concerns about the ability to meet short-term obligations without dilution. The deteriorating financial trend from a $1.2M profit in 2022 to a $2.0M loss in 2024 demonstrates a lack of operational stability and increasing burn rates that threaten long-term survival.
About Yubo International Biotech Ltd
Yubo International Biotech Ltd (YBGJ) is a biotechnology entity focused on developing innovative medical technologies and therapeutics to address unmet clinical needs. The company operates within the competitive global healthcare sector, leveraging research and development to potentially deliver breakthrough solutions for various patient populations. Despite limited recent revenue visibility, the firm maintains a strategic asset base aimed at long-term market penetration in specialized therapeutic areas.
Analysis
Management Discussion
Management is facing severe financial headwinds, highlighted by a sharp contraction in revenue to zero and a widening net loss of $2.0M in the most recent period compared to a previous year's $1.2M profit. The balance sheet reflects this distress with current liabilities significantly outpacing current assets and a substantial retained earnings deficit of $6.7M, suggesting a critical need for capital raising or asset monetization. Despite depreciation and amortization totaling nearly $170k, the operating cash flow remains negative at -$1.3M, indicating that core business activities are not yet self-sustaining.
Industry Overview
The biotechnology industry is characterized by high capital intensity, long development cycles, and binary outcomes where successful drug candidates can generate massive returns while failures result in total loss of investment. Companies often rely on venture capital or public markets to fund research until products reach late-stage clinical trials and receive regulatory approval for commercialization. This sector rewards innovation but carries elevated risks of bankruptcy before achieving a profitable milestone.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $104.3K | $604.7K | $3.5K |
| Cost of Revenue | $51.6K | $185.5K | $822 |
| Gross Profit | $52.7K | $419.2K | $2.6K |
| Operating Expenses | $1.3M | $1.6M | $1.8M |
| Operating Income | $-1.2M | $-1.2M | $-1.8M |
| D&A | $18.1K | $178.3K | $169.9K |
| Amortization | $9.4K | $11.7K | $13.4K |
| Non-Operating Income | $229 | $-377 | $-211.9K |
| Pre-Tax Income | $-1.2M | $-1.2M | $-2.0M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-1.2M | $-1.2M | $-2.0M |
| Discontinued Ops | $2.4M | $0 | $0 |
| Net Income | $1.2M | $-1.2M | $-2.0M |
| Minority Interest | $0 | $0 | $-206.5K |
| Net to Common | $1.2M | $-1.2M | $-1.8M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $750.0K | $725.2K | $682.8K |
| Cash & Equivalents | $18.2K | $6.4K | $7.0K |
| Inventory | $322.2K | $214.6K | $37.0K |
| Other Current Assets | $409.6K | $504.3K | $638.8K |
| Long-Term Assets | $1.6M | $942.0K | $852.1K |
| PP&E (Net) | $616.7K | $375.2K | $205.9K |
| Intangibles | $67.7K | $54.4K | $50.5K |
| Operating Leases | $790.5K | $391.9K | $478.8K |
| Other LT Assets | $123.7K | $120.5K | $116.9K |
| Total Assets | $2.3M | $1.7M | $1.5M |
| Current Liabilities | $2.5M | $3.4M | $4.7M |
| Current Leases | $400.1K | $276.4K | $368.0K |
| Other Current Liab | $2.1M | $3.1M | $4.4M |
| Long-Term Liabilities | $390.4K | $115.5K | $110.8K |
| LT Operating Leases | $390.4K | $115.5K | $110.8K |
| Other LT Liab | $0 | $0 | $0 |
| Total Liabilities | $2.9M | $3.5M | $4.8M |
| Shareholders' Equity | $-565.4K | $-1.8M | $-3.3M |
| Paid-In Capital | $2.9M | $2.9M | $3.0M |
| Retained Earnings | $-3.7M | $-4.9M | $-6.7M |
| AOCI | $70.0K | $-13.2K | $127.0K |
| Total L&E | $2.3M | $1.7M | $1.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $1.2M | $-1.2M | $-2.0M |
| Non-Cash Adjustments | $-1.8M | $190.0K | $481.5K |
| Working Capital Changes | $647.6K | $266.1K | $162.6K |
| Cash from Operations | $68.2K | $-739.0K | $-1.3M |
| Capital Expenditures | $0 | — | — |
| Cash from Investing | $-39.8K | $0 | $118.4K |
| Cash from Financing | $0 | $745.7K | $1.4M |
| FX Effect | $-37.8K | $-18.5K | $-187.2K |
| Net Change in Cash | $-9.3K | $-11.9K | $656 |
| Beginning Cash | $27.5K | $18.2K | $6.4K |
| Ending Cash | $18.2K | $6.4K | $7.0K |
Frequently Asked Questions
How does Yubo International Biotech Ltd make money?
1) Clinical R&D and Development: The primary segment involves research activities to discover and develop novel therapeutics, evidenced by significant non-cash adjustments and intangible assets. 2) Licensing and Collaboration: Potential revenue streams may include licensing agreements or strategic partnerships with larger pharmaceutical entities, though current operating cash flow is negative. 3) Intellectual Property Management: The company holds a portfolio of patents and proprietary technologies aimed at securing market exclusivity in specific disease states.
What are the main risks for YBGJ?
1) Significant Operating Losses: The company recorded a net profit deficit of $2.0M in the latest year, indicating substantial burn rates that require external capital to sustain operations. 2) Weak Liquidity Position: With current liabilities exceeding assets ($4.7M vs $682k current assets) and a shareholders' equity deficit of $3.3M, the firm faces potential solvency challenges. 3) Lack of Revenue Generation: After a drop from $0.6M in 2023 to $0.0M in 2024, the company has shown an inability to commercialize products or generate consistent cash flow from operations.
What is YBGJ's competitive advantage?
1) Proprietary Technology Platform: Access to unique, non-cash asset adjustments suggests a strong internal R&D engine capable of generating differentiated drug candidates. 2) Strategic Partnership Potential: Biotech firms often rely on external funding and collaborations to offset high operating expenses, positioning YBGJ for potential milestone payments. 3) Niche Market Focus: By targeting specific unmet medical needs, the company can establish a defensible position against larger competitors who may overlook smaller, specialized indications.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.